Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Dynavax Technologies Corporation (DVAX)

NEW YORK, Sept. 6, 2016

The investigation concerns whether Dynavax and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On September 2, 2016, the U.S. Food and Drug Administration ("FDA") revealed that it has cancelled Dynavax's upcoming meeting with the Vaccines and Related Biological Products Advisory Committee, that was scheduled for November 16, 2016, "to allow time for the FDA to review and resolve several outstanding issues" with Dynavax's Biologics License Application for HEPLISAV-B™. The FDA said that if necessary it would reschedule a meeting. Following this news Dynavax stock dropped $5.03, or 32%, to close at $10.91per share on September 2, 2016.

If you purchased Dynavax shares or if you are aware of any facts relating to this investigation, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/dvax. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484 or via email info@bgandg.com.  Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-dynavax-technologies-corporation-dvax-300322515.html